First Horizon Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

First Horizon Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$1.06K	–	2345
2025 Q1	$1.06K	Hold	15	–	–	﹤0.01%	2119
2024 Q4	$986	Sell	15 -89	-86%	-$5.96K	﹤0.01%	2099
2024 Q3	$7.31K	Sell	104 -472	-82%	-$39.5K	﹤0.01%	1708
2024 Q2	$47.4K	Hold	576	–	–	﹤0.01%	942
2024 Q1	$50.3K	Hold	576	–	–	﹤0.01%	939
2023 Q4	$55.5K	Buy	576 +144	+33%	+$12.7K	﹤0.01%	888
2023 Q3	$38.2K	Hold	432	–	–	﹤0.01%	969
2023 Q2	$37.4K	Sell	432 -79	-15%	-$7.43K	﹤0.01%	1015
2023 Q1	$49.7K	Hold	511	–	–	﹤0.01%	878
2022 Q4	$52.9K	Buy	511 +15	+3%	+$1.41K	﹤0.01%	835
2022 Q3	$41K	Sell	496 -39	-7%	-$3.47K	﹤0.01%	910
2022 Q2	$43K	Buy	535 +487	+1,015%	+$38.8K	﹤0.01%	983
2022 Q1	$4K	Sell	48 -206	-81%	-$17.2K	﹤0.01%	1324
2021 Q4	$22K	Buy	254 +2	+0.8%	+$165	﹤0.01%	1232
2021 Q3	$19K	Sell	252 -409	-62%	-$32.3K	﹤0.01%	1295
2021 Q2	$54K	Sell	661 -56	-8%	-$4.44K	﹤0.01%	748
2021 Q1	$53K	Buy	717 +61	+9%	+$4.98K	﹤0.01%	716
2020 Q4	$57K	Buy	656 +204	+45%	+$16.2K	﹤0.01%	556
2020 Q3	$33K	Buy	452 +60	+15%	+$6.07K	﹤0.01%	656
2020 Q2	$47K	Hold	392	–	–	﹤0.01%	538
2020 Q1	$32K	Buy	392 +59	+18%	+$5.08K	﹤0.01%	576
2019 Q4	$27K	Hold	333	–	–	﹤0.01%	753
2019 Q3	$21K	Buy	333 +302	+974%	+$23.3K	﹤0.01%	823
2019 Q2	$2K	Hold	31	–	–	﹤0.01%	1379
2019 Q1	$2K	Buy	+31	New	+$2.87K	﹤0.01%	1400
2018 Q4	–	Sell	-7	Closed	–	–	1505
2018 Q3	$0	Hold	7	–	–	﹤0.01%	1531
2018 Q2	$0	Buy	+7	New	+$613	﹤0.01%	1540

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Horizon Advisors's BMRN Position: Q2 2025 in Review

First Horizon Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 15 shares — an estimated $1.06K sold.

First Horizon Advisors first reported a position in BMRN in Q2 2018 and held it in 27 quarters. The position peaked at $57K in Q4 2020. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

First Horizon Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
First Horizon Advisors sold 15 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $1.06K.
First Horizon Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 27 quarters.
First Horizon Advisors's BioMarin Pharmaceuticals position peaked at $57K in Q4 2020.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.